La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Exagen a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Exagen..

Exagen (NASDAQ:XGN) Azioni, Catena delle Opzioni

Exagen

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Exagen Inc

April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), valued between $3,003 and $45,000. According to the April filing, the transaction occurred on April 18, 2025.
Currently, Illumina shares are trading down 0.23% at $71.03.
<h3>What Representative Has Been Trading Recently</h3>
In the last three years, Thomas Kean completed 79 stock transactions totaling more than $345 thousand. Aon and Johnson &amp; Johnson stocks were among the largest trades. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): $15,001 - $50,000 Purchase</li>
<li>Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>): $1,001 - $15,000 Purchase</li>
<li>nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Thomas Kean's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Illumina</td>
<td>ILMN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-04-01</td>
</tr>
<tr>
<td>nVent Electric</td>
<td>NVT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-04-01</td>
</tr>
<tr>
<td>nVent Electric</td>
<td>NVT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-07</td>
</tr>
<tr>
<td>Amazon.com</td>
<td>AMZN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-02-26</td>
</tr>
<tr>
<td>Stryker</td>
<td>SYK</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S (Partial)</td>
<td>2025-02-26</td>
</tr>
</tbody>
</table>
To keep an eye on Thomas Kean's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/thomas-kean">real-time tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

News

Politics

Trading Ideas

General

ILMN

Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know

Keybanc analyst Tim Rezvan maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $1000 to $1070.

Price Target

Analyst Ratings

NFLX

Keybanc Maintains Overweight on Netflix, Raises Price Target to $1070

Barclays analyst Matthew Bouley maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Equal-Weight and lowers the price target from $120 to $110.

Barclays Maintains Equal-Weight on D.R. Horton, Lowers Price Target to $110

Barclays analyst Benjamin Budish maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Equal-Weight and raises the price target from $129 to $136.

Barclays Maintains Equal-Weight on Blackstone, Raises Price Target to $136

Throughout a rocky 2025 market, AI has been a leading narrative in the Web3 world. Now, the U.S. government is trying to embrace the trend.
The U.S. Office of Management and Budget (OMB) is giving shape to President Donald Trump's executive order regarding AI leadership in the US by issuing <a href="https://www.whitehouse.gov/articles/2025/04/white-house-releases-new-policies-on-federal-agency-ai-use-and-procurement/">two directives </a>that define deadlines and specific policies for AI.
On January 23rd, Trump stated in an <a href="https://www.whitehouse.gov/presidential-actions/2025/01/removing-barriers-to-american-leadership-in-artificial-intelligence/">executive order</a> that the U.S. should "sustain and enhance America's global AI dominance." Trump repealed President Joe Biden&#8217;s October 2023 executive order on <a href="https://apnews.com/article/trump-ai-repeal-biden-executive-order-artificial-intelligence-18cb6e4ffd1ca87151d48c3a0e1ad7c1">AI safety</a>. Trump argued that Biden&#8217;s regulatory framework hampered innovation by requiring companies building AI models to coordinate with U.S. government oversight, especially regarding security, discrimination, privacy and labor rights. 
Although it's hard to see where the liquidity is, given Trump&#8217;s trade tariffs and subsequent decline in the digital asset market, AI is one of the dominant narratives of 2025.
"AI and Web3 are building each other up. AI becomes more reliable and fair, while Web3 becomes more intelligent and adaptive. That's why this combo is dominating the 2025 narrative," said  Roman Cyganov, founder &amp; CEO of Antix, an AI company that promises  "hyper-realistic digital twins for all."
According to a <a href="https://www.axios.com/2025/04/07/china-ai-race-stanford-report">Stanford report</a>, U.S. private and public sectors invested $109.1 billion last year in AI, which is nearly 12 times China&#8217;s $9.3 billion. In 2024, 78% of organizations were interested in implementing AI, but Meta, Anthropic, xAI have become credible rivals for OpenAI and Google, which were clearly in the lead in 2022. 
Antix focuses on adding a "human element" to its AI advancements by providing realistic avatars for its AI agents.
"Antix is centered around hyper-realistic digital humans because we believe the future of online interaction depends upon emotionally intelligent, visual-first communication,&#8221; Cyganov told Benzinga. &#8220;Static interfaces or text-based AI agents don't provoke trust, presence, or personality – 3D digital humans or avatars do. They're the bridge between the real and virtual world."
When asked how they would handle the dreaded uncanny valley, he said Antix focused on stylized realism, not photo-perfect replication. "We find that sweet spot where characters feel human enough to engage emotionally but not so close that they trip the uncanny valley wire. Our digital humans aren't just animated characters; they're context-aware, lifelike interfaces that can host, guide, entertain, and engage users with persistent identities across platforms. That's the next frontier of presence in digital interaction."
Antix says its realistic digital avatars for AI agents will not only serve as doppelgangers for public figures but can take the place of show hosts and key opinion leaders (KOLs) in and out of the Web3 space.
"Virtual KOLs can be always-on, fully brand-aligned, endlessly creative, and &#8211; crucially &#8211; data-driven. They don't need sleep, don't get canceled, and can scale content production massively. The key is believability, audience resonance, and performance," said the Antix CEO.
Cyganov acknowleged that blurring the line between realistic, AI-driven digital avatars and real humans is undesirable for users and projects. Antix has taken measures to draw a clear line between what's IRL and what's AI.
"We advocate for transparent AI design. Every Antix digital human should disclose their AI nature either explicitly or through subtle cues,&#8221; Cyganov explained. &#8220;The line between AI and human interaction is becoming more fluid. The goal isn't to trick people &#8212; it's to create emotionally resonant interactions. Regulation and design standards will be key in setting healthy boundaries as these agents become more widespread."
Cyganov suggested that Antix digital AI avatars are perfect for entertainment and lifestyle brands that can benefit from an always-on, tireless digital performer. "Imagine a music label launching a digital twin of an artist that engages fans 24/7, hosts AMAs, co-creates music with fans, and rewards community interaction via tokens. It's a blend of AI, IP extension, and community marketing. Other killer use cases include virtual event hosts, brand avatars for e-commerce, and interactive characters in digital fashion or Web3-native games."
In its current state, the capabilities of AI seem to be limited chiefly by the imagination of users and projects, with its true potential waiting to be revealed in new, novel use cases.
"Antix isn't just about building digital avatars &#8211; it's about shaping how humans interact with machines, brands, and each other in the next internet era. We combine the emotional depth of human storytelling, the scalability of AI, and the ethos of Web3. It's a new category: &#8216;Emotionally Intelligent, Tokenized Presence.&#8217; And we're just getting started," Cyganov said.
Antix has collaborated with HBO, Warner Bros, EA Sports, Tencent, and Porsche, where they were able to implement parts of their technology.
Photo: Shutterstock

Exclusives

Tech

Media

Interview

Exclusive: Antix CEO On Creating Hyper-Realistic Digital AI Avatars

Barclays analyst Jiong Shao maintains Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) with a Equal-Weight and lowers the price target from $95 to $90.

BIDU

Barclays Maintains Equal-Weight on Baidu, Lowers Price Target to $90

Keybanc analyst Tim Rezvan maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Overweight and lowers the price target from $72 to $60.

MTDR

Keybanc Maintains Overweight on Matador Resources, Lowers Price Target to $60

Barclays analyst Dan Levy maintains Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) with a Overweight and raises the price target from $97 to $105.

Barclays Maintains Overweight on Autoliv, Raises Price Target to $105

WIIM

Ford shares are trading lower amid reports indicating the company stopped exporting certain high-end vehicles to China due to increased tariffs.

Keybanc analyst Tim Rezvan maintains Kimbell Royalty Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>) with a Overweight and lowers the price target from $20 to $18.

Keybanc Maintains Overweight on Kimbell Royalty Partners, Lowers Price Target to $18

Barclays analyst Raimo Lenschow maintains ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) with a Equal-Weight and lowers the price target from $13 to $9.

Barclays Maintains Equal-Weight on ZoomInfo Technologies, Lowers Price Target to $9

Keybanc analyst Tim Rezvan maintains Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) with a Overweight and lowers the price target from $154 to $145.

ITGR

Keybanc Maintains Overweight on Integer Holdings, Lowers Price Target to $145

Barclays analyst Raimo Lenschow maintains Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) with a Underweight and lowers the price target from $25 to $22.

Barclays Maintains Underweight on Teradata, Lowers Price Target to $22

Keybanc analyst Tim Rezvan maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and lowers the price target from $234 to $216.

INSP

Keybanc Maintains Overweight on Inspire Medical Systems, Lowers Price Target to $216

Barclays analyst Raimo Lenschow maintains Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Overweight and lowers the price target from $34 to $26.

Barclays Maintains Overweight on Sprout Social, Lowers Price Target to $26

Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares are trading lower by 12.6% to $84.87 over the trailing week. Investors are weighing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44868970/nvidia-amd-take-a-17-billion-hit-in-the-ai-arms-race-while-broadcom-remains-shielded-says-analyst">new U.S. government restrictions</a> on AI chip exports to China and several other regions. 
The restrictions have elevated concerns about the company&#8217;s exposure to geopolitical risk and supply chain disruptions in key international markets.
What To Know: The latest measures from the U.S. government—expanding upon the Biden administration's ongoing strategy to limit China's access to advanced AI hardware—now require AMD to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44868970/nvidia-amd-take-a-17-billion-hit-in-the-ai-arms-race-while-broadcom-remains-shielded-says-analyst">obtain licenses</a> to sell its MI308 data center GPUs in China, Hong Kong, Macau and countries listed under the Department of Commerce&#8217;s <a href="https://www.benzinga.com/news/25/04/44876468/whats-going-on-with-amd-stock-14">&#8220;D:5&#8221; designation</a>, which includes nations of national security concern.
Read Also: <a href="https://www.benzinga.com/25/04/44861917/broadcom-marvell-synopsys-the-chips-that-might-not-crumble-in-the-coming-storm">Broadcom, Marvell, Synopsys: The Chips That Might Not Crumble In The Coming Storm</a>
The MI308 is AMD's <a href="https://www.benzinga.com/government/regulations/25/04/44844097/amd-flags-800-million-risk-from-new-us-chip-export-rules-as-china-tariffs-add-pressure">most advanced data center GPU</a> to date, designed for training and inferencing large AI models. It directly competes with NVIDIA Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) H100 in high-performance computing applications and forms a crucial pillar of AMD's push into AI infrastructure markets.
The licensing requirements now create an additional bottleneck for AMD in a region that had been a significant source of demand for its AI accelerators.
Financial Fallout: In anticipation of a sharp decline in sales to China, AMD has taken a one-time <a href="https://www.benzinga.com/government/regulations/25/04/44844097/amd-flags-800-million-risk-from-new-us-chip-export-rules-as-china-tariffs-add-pressure">inventory charge of $800 million</a> related to unsold or redirected chips and expects a $1.5 billion to $1.8 billion hit to revenue—equivalent to roughly 10% of its projected 2025 data center business.
This comes at a critical moment for AMD, as it has aggressively ramped up its AI ambitions through investments in hardware, <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43788975/amd-closing-competitive-gpu-gap-with-nvidia-gains-market-share-from-intel-in-client-and-server-markets-analyst">software stacks like ROCm</a> and ecosystem partnerships.
Broader Implications: The export restrictions are part of a broader U.S. effort to curtail China&#8217;s access to cutting-edge AI hardware amid growing national security tensions. 
While demand for AI infrastructure in China remains robust, analysts expect an accelerated pivot toward domestically developed solutions, such as <a href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china">Huawei's Ascend AI chips</a>.
This shift could undercut AMD&#8217;s long-term positioning in one of the world&#8217;s largest tech markets. Unlike NVIDIA, which benefits from <a href="https://www.benzinga.com/insights/news/25/04/44842135/understanding-nvidias-position-in-semiconductors-amp-semiconductor-equipment-industry-compared-to-c">stronger software ecosystems (CUDA)</a> and more diverse hardware offerings, AMD is still in the earlier stages of building out a comprehensive AI platform.
Custom silicon developers and hyperscalers designing in-house chips <a href="https://www.benzinga.com/25/04/44861917/broadcom-marvell-synopsys-the-chips-that-might-not-crumble-in-the-coming-storm">remain unaffected by the new rules</a>—giving them a strategic edge over traditional chipmakers like AMD, whose offerings are subject to export controls.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44896834/dollar-hits-3-year-lows-us-stocks-tumble-as-trump-threatens-to-fire-powell-contrarians-of-the-world-unite">Dollar Hits 3-Year Lows, US Stocks Tumble As Trump Threatens To Fire Powell: &#8216;Contrarians Of The World, Unite!&#8217;</a>
Investors can gain exposure to&nbsp;AMD by&nbsp;investing&nbsp;in the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>).
<h2 class="wp-block-heading">How To Buy AMD Stock</h2>
By now you're likely curious about how to participate in the market for Advanced Micro Devices &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Advanced Micro Devices, which is trading at $85.34 as of publishing time, $100 would buy you 1.17 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMD has a 52-week high of $187.28 and a 52-week low of $76.48.

NVDA

AMD Stock Drops Amid AI Chip Export Ban: What's Going On?

Barclays analyst Raimo Lenschow maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Overweight and lowers the price target from $1200 to $967.

Barclays Maintains Overweight on ServiceNow, Lowers Price Target to $967

Keybanc analyst Tim Rezvan maintains Infinity Natural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) with a Overweight and lowers the price target from $26 to $24.

Morgan Stanley Market Vectors Rupee/USD ETN

Keybanc Maintains Overweight on Infinity Natural, Lowers Price Target to $24

Barclays analyst Raimo Lenschow maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Equal-Weight and lowers the price target from $97 to $84.

PEGA

Barclays Maintains Equal-Weight on Pegasystems, Lowers Price Target to $84

Barclays analyst Raimo Lenschow maintains Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Equal-Weight and lowers the price target from $231 to $204.

PCTY

Barclays Maintains Equal-Weight on Paylocity Holding, Lowers Price Target to $204

Press Releases

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

Earnings

Exagen Inc. Reports Third Quarter 2024 Results

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Health Care

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Comments

Exagen

Exagen (XGN) Opzioni

Exagen (NASDAQ:XGN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO